 |
|
Trends in Helicobacter pylori eradication rates by first-line triple therapy and related factors in eradication therapy
Sung Eun Kim, Moo In Park, Seun Ja Park, Won Moon, Youn Jung Choi, Ji Hyun Cheon, Hye Jung Kwon, Ki Hwan Ku, Chang Hun Yoo, Jae Hyun Kim, Gyu Won Lee, Sung Eun Song
Korean J Intern Med. 2015;30(6):801-807. Published online 2015 Oct 30 DOI: https://doi.org/10.3904/kjim.2015.30.6.801
|
|
Citations to this article as recorded by
 Antibiotic Resistance of Helicobacter pylori: Mechanisms and Clinical Implications
Md Hasanuzzaman, Chang Seok Bang, Eun Jeong Gong
Journal of Korean Medical Science.2024;[Epub] CrossRef Predictors of Successful First-Line Helicobacter pylori Eradication with Fluoroquinolones in Pakistan: A Prospective Exploration of Demographic and Clinical Factors
Sumaira Khadim, Iyad Naeem Muhammad, Tanveer Alam, Shahnaz Usman, Hina Rehman, Sajjad Haider
Antibiotics.2024; 13(3): 211. CrossRef Development and validation of next-generation sequencing panel for personalized Helicobacter pylori eradication treatment targeting multiple species
Byung-Joo Min, Myung-Eui Seo, Jung Ho Bae, Ji Won Kim, Ju Han Kim
Frontiers in Cellular and Infection Microbiology.2024;[Epub] CrossRef Novel Drug-like HsrA Inhibitors Exhibit Potent Narrow-Spectrum Antimicrobial Activities against Helicobacter pylori
Javier Casado, Irene Olivan-Muro, Sonia Algarate, Eduardo Chueca, Sandra Salillas, Adrián Velázquez-Campoy, Elena Piazuelo, María F. Fillat, Javier Sancho, Ángel Lanas, Andrés González
International Journal of Molecular Sciences.2024; 25(18): 10175. CrossRef Effectiveness of eradication therapy for Helicobacter pylori infection in Africa: a systematic review and meta-analysis
Sintayehu Fekadu, Hizkel Engiso, Sisay Seyfe, Hisashi Iizasa, Ashebir Godebo, Serawit Deyno, Hironori Yoshiyama
BMC Gastroenterology.2023;[Epub] CrossRef Antimicrobial Resistance Molecular Mechanisms of Helicobacter pylori in Jordanian Children: A Cross-Sectional Observational Study
Salma Burayzat, Mohammad Al-Tamimi, Mohammad Barqawi, Mustafa Sabri Massadi, Jumanah Abu-Raideh, Hadeel Albalawi, Ashraf I. Khasawneh, Nisreen Himsawi, Maha Barber
Antibiotics.2023; 12(3): 618. CrossRef Novel Mutations Conferring Amoxicillin Resistance in Helicobacter pylori in South Korea
Soon Young Park, Eun Hwa Lee, Dokyun Kim, Young Goo Song, Su Jin Jeong
Antibiotics.2023; 12(4): 748. CrossRef The Suitability of Stool Antigen Testing in the Detection of Helicobacter pylori in a Regional and Rural Area of Australia
Timothy Wearne, Safaa Nadeem, Bruce Wilson, Kylie J. Mansfield, Caitlin Keighley, Sreedhari Thayalasekaran
GastroHep.2023; 2023: 1. CrossRef Alcohol increases treatment failure for Helicobacter pylori eradication in Asian populations
Jing Yu, Yiming Lv, Peng Yang, Yizhou Jiang, Xiangrong Qin, Xiaoyong Wang
BMC Gastroenterology.2023;[Epub] CrossRef Optimal treatment duration of bismuth-containing quadruple therapy in Helicobacter pylori infection: A retrospective study
Ji Yoon Kim, Sang Gyun Kim, Soo-Jeong Cho
Medicine.2023; 102(48): e36310. CrossRef Impact of smoking on the eradication of Helicobacter pylori
Jing Yu, Peng Yang, Xiangrong Qin, Chunjian Li, Yiming Lv, Xiaoyong Wang
Helicobacter.2022;[Epub] CrossRef Helicobacter pylori eradication in renal transplant candidates
Mariana E. Maioli, Raquel F. N. Frange, Cintia M. C. Grion, Vinicius D. A. Delfino
Brazilian Journal of Nephrology.2022; 44(2): 215. CrossRef Efficacy of Twice a Day Bismuth Quadruple Therapy for Second-Line Treatment of Helicobacter pylori Infection
Jeemyoung Kim, Eun Jeong Gong, Myeongsook Seo, Hyun Il Seo, Jong Kyu Park, Sang Jin Lee, Koon Hee Han, Woo Jin Jeong, Young Don Kim, Gab Jin Cheon
Journal of Personalized Medicine.2022; 12(1): 56. CrossRef Helicobacter pylori infection treatment in the United States: clinical consequences and costs of eradication treatment failure
Shailja Shah, Elizabeth Hubscher, Corey Pelletier, Rinu Jacob, Lydia Vinals, Rena Yadlapati
Expert Review of Gastroenterology & Hepatology.2022; 16(4): 341. CrossRef Factors Affecting the Intraluminal Therapy for Helicobacter pylori Infection
Cheng-Yu Ho, Ting-Wen Liu, Yang-Sheng Lin, Yen-Po Chen, Ming-Jen Chen, Horng-Yuan Wang, Tai-Cherng Liou
Microorganisms.2022; 10(2): 415. CrossRef Successful Eradication of Helicobacter pylori with 5-Day Concomitant Treatment
Lia Goldberg, Thomas J. Amrick, Than Than Aye
GastroHep.2022; 2022: 1. CrossRef Eradication Rate Using a First-line Triple Therapy for Helicobacter pylori Infection in Yeongdong, Gangwon Province, Korea
Eun Jeong Gong, Chang Seok Bang, Myeongsook Seo, Hyun Il Seo, Jong Kyu Park, Sang Jin Lee, Koon Hee Han, Woo Jin Jeong, Young Don Kim, Gab Jin Cheon
The Korean Journal of Helicobacter and Upper Gastrointestinal Research.2022; 22(2): 139. CrossRef Gastrointestinal adverse reactions reduce the success rate of Helicobacter pylori eradication therapy: A multicenter prospective cohort study
Toshihiko Kakiuchi, Muneaki Matsuo, Hiroyoshi Endo, Yasuhisa Sakata, Motohiro Esaki, Takahiro Noda, Ichiro Imamura, Kazutoshi Hashiguchi, Shinichi Ogata, Yasuhiko Fujioka, Keiichiro Hanada, Kayoko Fukuda, Masaya Yoshimura, Tetsuro Kajiwara, Kentaroh Yamam
Helicobacter.2021;[Epub] CrossRef A 10- or 14-day Bismuth-containing Quadruple Therapy as a First-line Helicobacter pylori Eradication Therapy: A Systematic Review and Meta-analysis
Sung Eun Kim, Hye-Kyung Jung, Seung Joo Kang, Yong Chan Lee, Hyo-Joon Yang, Seon-Young Park, Cheol Min Shin, Hyun Chul Lim, Jie-Hyun Kim, Su Youn Nam, Woon Geon Shin, Jae Myung Park, Il Ju Choi, Jae Gyu Kim, Miyoung Choi
The Korean Journal of Helicobacter and Upper Gastrointestinal Research.2021; 21(1): 48. CrossRef Seven-day triple therapy is sufficient to eradicate infection caused by Helicobacter pylori without 23S rRNA point mutation
Jung Wook Lee, Su Jin Kim, Cheol Woong Choi, Hyeong Jin Kim, Dae Hwan Kang, Hyung Wook Kim, Su Bum Park, Hyeong Seok Nam, Dae Gon Ryu
Medicine.2021; 100(21): e26133. CrossRef Management of Helicobacter pylori infection: The Bhubaneswar Consensus Report of the Indian Society of Gastroenterology
Shivaram Prasad Singh, Vineet Ahuja, Uday C. Ghoshal, Govind Makharia, Usha Dutta, Showkat Ali Zargar, Jayanthi Venkataraman, Amit Kumar Dutta, Asish K Mukhopadhyay, Ayaskanta Singh, Babu Ram Thapa, Kim Vaiphei, Malathi Sathiyasekaran, Manoj K. Sahu, Nira
Indian Journal of Gastroenterology.2021; 40(4): 420. CrossRef Evaluation of the Effectiveness of Helicobacter pylori Eradication Regimens in Lithuania during the Years 2013–2020: Data from the European Registry on Helicobacter pylori Management (Hp-EuReg)
Paulius Jonaitis, Juozas Kupcinskas, Olga P. Nyssen, Ignasi Puig, Javier P. Gisbert, Laimas Jonaitis
Medicina.2021; 57(7): 642. CrossRef Types of 23S Ribosomal RNA Point Mutations and Therapeutic Outcomes for Helicobacter pylori
Sang Yoon Kim, Jae Myung Park, Chul-Hyun Lim, Hye Ah Lee, Ga-Yeong Shin, Younghee Choe, Yu Kyung Cho, Myung-Gyu Choi
Gut and Liver.2021; 15(4): 528. CrossRef Vaccine development against Helicobacter pylori: from ideal antigens to the current landscape
Irineu Dos Santos Viana, Maria Luísa Cordeiro Santos, Hanna Santos Marques, Vinícius Lima de Souza Gonçalves, Breno Bittencourt de Brito, Filipe Antônio França da Silva, Natália Oliveira e Silva, Fillipe Dantas Pinheiro, Adriano Fernandes Teixeira, Davi T
Expert Review of Vaccines.2021; 20(8): 989. CrossRef Pretreatment with Ranitidine Bismuth Citrate May Improve Success Rates of Helicobacter pylori Eradication: A Prospective, Randomized, Controlled and Open-Label Study
Jin Young Yoon, Min Seob Kwak, Jung Won Jeon, Jae Myung Cha
The Tohoku Journal of Experimental Medicine.2021; 255(1): 41. CrossRef
Hydrogen Peroxide-Mediated Oxygen Enrichment Eradicates Helicobacter pylori
In Vitro
and
In Vivo
Jia Di, Jun Zhang, Lei Cao, Ting-ting Huang, Jun-xia Zhang, Yan-ni Mi, Xue Xiao, Ping-ping Yan, Man-li Wu, Tong Yao, Dong-zheng Liu, Jing Liu, Yong-xiao Cao
Antimicrobial Agents and Chemotherapy.2020;[Epub] CrossRef The Prevalence of Multidrug Resistance of Helicobacter pylori and Its Impact on Eradication in Korea from 2017 to 2019: A Single-Center Study
Jae Yong Park, Tae-Seop Shin, Ji Hyun Kim, Hong Jip Yoon, Beom Jin Kim, Jae Gyu Kim
Antibiotics.2020; 9(10): 646. CrossRef Efficacy of Seven-day High-dose Esomeprazole-based Triple Therapy versus Seven-day Standard Dose Non-esomeprazole-based Triple Therapy as the First-line Treatment of Patients with Helicobacter pylori Infection
Young Dal Lee, Sung Eun Kim, Seun Ja Park, Moo In Park, Won Moon, Jae Hyun Kim, Kyoungwon Jung, Jiyun Song
The Korean Journal of Gastroenterology.2020; 76(3): 142. CrossRef Levofloxacin-Based Regimen Versus Bismuth Quadruple Regimen for Helicobacter pylori Eradication in Kurdistan Region, Iraq
Nawfal R Hussein, Shahram A Mirkhan, Ali A Ramadhan, Ramdhan S Issa, Ibrahim A. Naqid, Bawer Yassin, Sollen S Hasso, Reving S Salih, Shaimaa A Mahmood
Avicenna Journal of Clinical Microbiology and Infection.2020; 7(3): 81. CrossRef Accuracy of the Helicobacter pylori diagnostic tests in patients with peptic ulcer bleeding: a systematic review and network meta-analysis
Nóra Vörhendi, Alexandra Soós, Marie Anne Engh, Benedek Tinusz, Zsolt Szakács, Dániel Pécsi, Alexandra Mikó, Patrícia Sarlós, Péter Hegyi, Bálint Eröss
Therapeutic Advances in Gastroenterology.2020;[Epub] CrossRef Gastric juice‐based PCR assay: An alternative testing method to aid in the management of previously treated Helicobacter pylori infection
Meng‐Shu Hsieh, Chung‐Jung Liu, Wen‐Hung Hsu, Chia‐Jung Li, Pei‐Yun Tsai, Huang‐Ming Hu, Hsiang‐Yao Shih, Chien‐Yu Lu, Fang‐Jung Yu, Fu‐Chen Kuo, Deng‐Chyang Wu, Chao‐Hung Kuo
Helicobacter.2019;[Epub] CrossRef Effect of 7-day Bismuth Quadruple Therapy versus 14-day Moxifloxacin Triple Therapy for Second-line Helicobacter pylori Eradication Therapy
Sung Eun Kim, Ji Hun Roh, Moo In Park, Seun Ja Park, Won Moon, Jae Hyun Kim, Kyoungwon Jung, Jae Joon Heo
The Korean Journal of Gastroenterology.2019; 73(1): 26. CrossRef Can Aminoglycosides Be Used as a New Treatment forHelicobacter pylori?In vitroActivity of Recently IsolatedHelicobacter pylori
Kyoung Hwa Lee, Soon Young Park, Su Jin Jeong, Da Hyun Jung, Jie-Hyun Kim, Seok Hoon Jeong, Il-Mo Kang, Young Goo Song
Infection & Chemotherapy.2019; 51(1): 10. CrossRef Predictors of triple therapy treatment failure among H. pylori infected patients attending at a tertiary hospital in Northwest Tanzania: a prospective study
Hyasinta Jaka, Andreas Mueller, Christa Kasang, Stephen E. Mshana
BMC Infectious Diseases.2019;[Epub] CrossRef Comparative Study between Two Triple-therapy Regimens in Treating Helicobacter pylori: Related Peptic Ulcer Disease
Gokul D Yatheendranathan, Sudhakar Ankaiya, J Lalith Kumar
SBV Journal of Basic, Clinical and Applied Health Science.2019; 2(3): 108. CrossRef Erradicación de la infección por Helicobacter pylori con una nueva terapia cuádruple basada en bismuto en la práctica clínica
Elena Pérez-Arellano, María Isabel Rodriguez-Garcia, Ana Belen Galera Rodenas, Emilio de la Morena-Madrigal
Gastroenterología y Hepatología.2018; 41(3): 145. CrossRef Inappropriate treatment in Helicobacter pylori eradication failure: a retrospective study
Huiyi Li, Xiao Liang, Qi Chen, Wei Zhang, Hong Lu
Scandinavian Journal of Gastroenterology.2018; 53(2): 130. CrossRef Sex differences in urea breath test results for the diagnosis of Helicobacter pylori infection: a large cross-sectional study
Ido Eisdorfer, Varda Shalev, Sophy Goren, Gabriel Chodick, Khitam Muhsen
Biology of Sex Differences.2018;[Epub] CrossRef Eradication of Helicobacter pylori infection with a new bismuth-based quadruple therapy in clinical practice
Elena Pérez-Arellano, María Isabel Rodriguez-Garcia, Ana Belen Galera Rodenas, Emilio de la Morena-Madrigal
Gastroenterología y Hepatología (English Edition).2018; 41(3): 145. CrossRef IVTH BRAZILIAN CONSENSUS CONFERENCE ON HELICOBACTER PYLORI INFECTION
Luiz Gonzaga Vaz COELHO, James Ramalho MARINHO, Robert GENTA, Laercio Tenório RIBEIRO, Maria do Carmo Friche PASSOS, Schlioma ZATERKA, Paulo Pimentel ASSUMPÇÃO, Alfredo José A BARBOSA, Ricardo BARBUTI, Lucia Libanês BRAGA, Helenice BREYER, Aloisio CARVALH
Arquivos de Gastroenterologia.2018; 55(2): 97. CrossRef Clinical relevance of point mutations in the 23S rRNA gene in Helicobacter pylori eradication
Chang-Geun Park, Seohyeon Kim, Eun-Ju Lee, Hyo-Sung Jeon, Seungwoo Han
Medicine.2018; 97(33): e11835. CrossRef Peptide Nucleic Acid Probe-Based Analysis as a New Detection Method for Clarithromycin Resistance inHelicobacter pylori
Da Hyun Jung, Jie-Hyun Kim, Su Jin Jeong, Soon Young Park, Il-Mo Kang, Kyoung Hwa Lee, Young Goo Song
Gut and Liver.2018; 12(6): 641. CrossRef Triple therapy versus sequential therapy for the first-line Helicobacter pylori eradication
Ji Young Chang, Ki-Nam Shim, Chung Hyun Tae, Ko Eun Lee, Jihyun Lee, Kang Hoon Lee, Chang Mo Moon, Seong-Eun Kim, Hye-Kyung Jung, Sung-Ae Jung
BMC Gastroenterology.2017;[Epub] CrossRef Levofloxacin or Clarithromycin-based quadruple regimens: what is the best alternative as first-line treatment for Helicobacter pylori eradication in a country with high resistance rates for both antibiotics?
Diogo Branquinho, Nuno Almeida, Carlos Gregório, José Eduardo Pina Cabral, Adriano Casela, Maria Manuel Donato, Luís Tomé
BMC Gastroenterology.2017;[Epub] CrossRef
Helicobacter pylori Eradication Rate in Patients with Diabetes
Jiyeon Yoo, Yeong Ji Yu, Gumin Cho, Hongkwon Oh, Seung Hyun Oh, Tae Ho Kim, Jung Hwan Oh
The Korean Journal of Helicobacter and Upper Gastrointestinal Research.2017; 17(2): 83. CrossRef Efficacy and safety of rifaximin associated with standard triple therapy (omeprazole, clarithromycin and amoxicillin) for H. pylori eradication: A phase IV pilot clinical trial
Mercedes Ramas, Maria G. Donday, Adrian G. McNicholl, Javier P. Gisbert
Gastroenterología y Hepatología.2017; 40(10): 658. CrossRef The Efficacy of Moxifloxacin-containing Triple Therapy after Hybrid Therapy Failure inHelicobacter pyloriEradication
Soohoon Kwon, Dong Ho Lee, Jae Bin Kang, Nayoung Kim, Young Soo Park, Cheol Min Shin, Hyuk Yoon, Yoon Jin Choi
The Korean Journal of Gastroenterology.2017; 70(2): 72. CrossRef Second-line bismuth-containing quadruple therapy for Helicobacter pylori eradication and impact of diabetes
Sung Eun Kim, Moo In Park, Seun Ja Park, Won Moon, Jae Hyun Kim, Kyoungwon Jung, Hae Koo Kim, Young Dal Lee
World Journal of Gastroenterology.2017; 23(6): 1059. CrossRef Efficacy and safety of rifaximin associated with standard triple therapy (omeprazole, clarithromycin and amoxicillin) for H. pylori eradication: A phase IV pilot clinical trial
Mercedes Ramas, Maria G. Donday, Adrian G. McNicholl, Javier P. Gisbert
Gastroenterología y Hepatología (English Edition).2017; 40(10): 658. CrossRef
A High-Throughput Multiplex Genetic Detection System for
Helicobacter Pylori
Identification, Virulence and Resistance Analysis
Binjie Hu, Fuju Zhao, Shiwen Wang, Michal A Olszewski, Haipeng Bian, Yong Wu, Mimi Kong, Lingli Xu, Yingxin Miao, Yi Fang, Changqing Yang, Hu Zhao, Yanmei Zhang
Future Microbiology.2016; 11(10): 1261. CrossRef The Influence of Iron Deficiency onHelicobacter pyloriEradication
Sung Eun Kim, Moo In Park, Seun Ja Park, Won Moon, Jae Hyun Kim, Kyoungwon Jung, Kwang Il Seo, Seong Kyeong Lim, Jin Kyu Jung, Hyeon Jin Kim, Go Eun Yeo, Sung Chan Jeon, Duk Song Cho, You Jin Han
The Korean Journal of Helicobacter and Upper Gastrointestinal Research.2016; 16(2): 82. CrossRef First‐line Helicobacter pylori eradication among patients with chronic liver diseases in Taiwan
Cheng‐En Tsai, Chih‐Ming Liang, Chen‐Hsiang Lee, Yuan‐Hung Kuo, Keng‐Liang Wu, Yi‐Chun Chiu, Wei‐Chen Tai, Seng‐Kee Chuah
The Kaohsiung Journal of Medical Sciences.2016; 32(8): 397. CrossRef Update on prevention and treatment of Helicobacter pylori infection
Zhao-Chun Chi
World Chinese Journal of Digestology.2016; 24(16): 2454. CrossRef
|